AusperBio raised $120 million in a Series C round to advance its oligonucleotide therapy for chronic hepatitis B through Phase 3 and beyond. The company’s strategy focuses on moving an oligo program with a defined clinical path toward registration while scaling capabilities for later-stage trials. The financing highlights continued capital commitment to nucleic-acid approaches in HBV, even as the field seeks therapies that more effectively suppress viral persistence and improve functional outcomes.